Don’t miss your opportunity to be a part of this event, now a highly anticipated Campbell tradition, a decade in the making!
More information at: library.campbell.edu/symposium2020
Back To Schedule
Friday, March 27 • 08:00 - 17:00
[VIRTUAL] Permeability and Uptake Study of Efavirenz Formulations in Caco-2 and Hep G2 Cells

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Feedback form is now closed.
Efavirenz (EFV) is an antiretroviral drug classified as non-nucleotide reverse transcriptase inhibitor (NNRTI). To achieve therapeutic plasma concentrations, patients need high doses of EFV (600 mg daily for adult) when administrated orally. This is mainly due to its low solubility which leads to dissolution-limiting poor transport in gut. This project is to test whether an albumin bound formulation will enhance cell transport and uptake of EFV by cells. Standard Caco-2 permeability assay and drug uptake assay by Hep G2 cells are ongoing. EFV oral suspension in commercial vehicle ORA-Plus® is used as the control.

Friday March 27, 2020 08:00 - 17:00 EDT